NCT06815627View on ClinicalTrials.gov

Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography

PHASE3RecruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 18, 2025

Primary Completion Date

February 28, 2027

Study Completion Date

February 28, 2027

Conditions
Cardiac Diseases
Interventions
DRUG

NH002 (Perflutren Lipid Microspheres) Injectable Suspension

NH002 is formulated as a microbubble injectable suspension for intravenous administration. NH002 requires an activation process prior to use.

Trial Locations (6)

11217

RECRUITING

Taipei Veterans General Hospital, Taipei

104217

RECRUITING

MacKay Memorial Hospital, Taipei

106438

RECRUITING

Cathay General Hospital, Taipei

204201

RECRUITING

Keelung Chang Gung Memorial Hospital & Lovers Lake Branch, Keelung

302058

RECRUITING

National Taiwan University Hospital Hsin-Chu Branch, Zhubei

404327

RECRUITING

China Medical University Hospital, Taichung

All Listed Sponsors
collaborator

CMIC ASIA-PACIFIC, PTE. LTD., TAIWAN BRANCH

UNKNOWN

lead

Trust Bio-sonics, Inc.

INDUSTRY

NCT06815627 - Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography | Biotech Hunter | Biotech Hunter